LinQ SI Joint Fusion: Posterior Approach Without Screws


LinQ is a posterior sacroiliac (SI) joint fusion option that places a structural cortical bone allograft inside the joint without metal screws. It is one tool within minimally invasive SI joint fusion—not a treatment for every cause of low-back or buttock pain. This page explains the device and approach. For general fusion candidacy, diagnostic injections, RFA versus fusion, and recovery frameworks, read the parent SI joint fusion guide. Screw-based detail: SacriX SI joint fusion.

Quick Answer: LinQ

  • LinQ (PainTEQ) places a structural cortical bone allograft in the SI joint through a posterior corridor.
  • It is a screw-free option. Some patients prefer that after reviewing tradeoffs with Dr. Sharma.
  • Regulatory shape in published reports: HCT/P tissue pathway (21 CFR 1271 / section 361)—not an FDA 510(k)-cleared metal fixation device.
  • Evidence includes prospective single-arm series (SECURE) and related reports; it is not a sham-controlled head-to-head proof against lateral screw systems.
  • Diagnosis still needs history, exam, imaging, and usually diagnostic SI joint blocks. Conservative care comes first.
  • Procedure setting here: hospital or surgery center. Sudden severe weakness or new bowel or bladder loss—call 911.

What Is the LinQ Implant System?

LinQ is manufactured by PainTEQ. Published descriptions call it a structural cortical bone allograft placed through a small posterior incision into the SI joint to support stabilization while fusion develops. The approach is image-guided. Instruments prepare the joint corridor; the allograft is seated within the joint. This page does not call those delivery instruments FDA-cleared or FDA-approved; no PainTEQ LinQ metal-fixation 510(k) was identified. Nothing in this description means biological fusion is already complete at the end of the case.

LinQ does not use metal screws that cross the joint. That is a practical difference some patients care about when they hear the word “screw.” Preferring no screws is a preference to discuss—not proof that LinQ is better or worse for every anatomy.

Regulatory Status: HCT/P, Not a 510(k) Metal Device

Peer-reviewed LinQ literature and clinic educational materials describe the implant as a human cells, tissues, and cellular and tissue-based product (HCT/P) regulated under Section 361 of the Public Health Service Act and 21 CFR Part 1271. FDA’s HCT/P framework focuses on donor eligibility, manufacturing controls, and reducing communicable-disease transmission risk. It is not the same pathway as FDA 510(k) clearance for a Class II sacroiliac fixation device.

An openFDA / accessdata search for a PainTEQ LinQ 510(k) number does not identify a LinQ metal SI fixation clearance. Do not call LinQ “FDA-approved” or “FDA-cleared” as if it were a 510(k) screw system. Ask which exact implant and labeling language apply to your plan. Clearance or tissue regulation of any product is not a promise of your result.

How This Page Fits Your Decision

At SpinePain Solutions, Dr. Amit Sharma performs SI joint fusion himself with both SacriX and LinQ. He uses bone graft in every case. In his practice, SacriX is often preferred for stability because screws cross the joint. LinQ remains an option for selected patients who prefer a posterior allograft without screws after reviewing open questions and tradeoffs. That practice pattern does not claim either company or device is universally superior.

Who Might Be Considered for LinQ?

Candidacy follows the same careful path as other SI fusion discussions:

  • Persistent, function-limiting pain reasonably localized to the SI joint.
  • A fair try at conservative care (therapy, activity changes, medicines when safe).
  • Competing lumbar and hip causes considered.
  • Convincing response to image-guided diagnostic SI joint injection during the anesthetic window, ideally during a normally painful activity.
  • Shared discussion of approach, including whether avoiding screws matters to you after hearing risks and evidence limits.

No single symptom, scan, or injection percentage establishes candidacy by itself. A helpful injection does not automatically mean fusion—or LinQ specifically—is next. Details on blocks and the pathway: SI joint fusion hub and SI joint injection.

How the LinQ Procedure Is Performed

  1. Planning: anatomy, prior implants, medical risk, medication instructions, and graft plan are reviewed.
  2. Positioning and anesthesia: individualized. Options may include local anesthetic only, conscious sedation, or MAC.
  3. Image-guided posterior access: fluoroscopy (and additional imaging when appropriate) guides a small posterior corridor to the joint.
  4. Joint preparation and allograft delivery: instruments prepare the joint surface; the structural cortical allograft is seated within the joint.
  5. Assessment and closure: imaging assesses position; the incision is closed; safe discharge is evaluated.

Many procedures are outpatient from a hospital or surgery center, but discharge depends on pain control, medical status, and safe mobility. Procedure duration and incision size vary; neither should be treated as a universal promise. Manufacturer materials sometimes discuss office settings for some posterior techniques; at SpinePain Solutions, fusion—including LinQ—is done in a hospital or surgery center unless your written plan says otherwise.

How LinQ Differs From Screw or Transiliac Systems

Topic LinQ (posterior allograft) SacriX (example screw/transiliac)
Corridor Posterior into the joint Lateral-oblique / transiliac across the joint
Hardware No screws; structural bone allograft Titanium screws across the joint
Regulatory language HCT/P tissue pathway (published descriptions) FDA 510(k) K232605
Evidence shape Prospective single-arm series; thinner comparative RCT base Lateral/transiliac literature is larger overall; still mixed

Neutral framing: more metal across the joint can mean more immediate mechanical hold for some anatomies; a screw-free allograft can matter to patients who want to avoid screws. Neither sentence proves better pain relief for you. Do not transfer triangular titanium lateral-implant trial results onto LinQ, or LinQ series results onto SacriX.

What the Evidence Shows—and Its Limits

The SECURE study is a multicenter, prospective, single-arm trial of the LinQ posterior allograft implant (ClinicalTrials.gov NCT04423120). Final published results report outcomes through 12 months in implanted participants and describe procedure-related adverse events; the design is not a double-blind sham comparison and is not a randomized head-to-head against SacriX or other lateral screw systems. An earlier interim report described six-month outcomes from the same program. Small retrospective series also exist. Consensus guidelines characterize posterior SI fusion evidence as lower certainty than some lateral literature, while noting that lateral MIS fusion evidence itself is conflicting in places.

Honest bottom line: LinQ evidence is limited single-arm prospective data (SECURE and related reports) with a thinner comparative evidence base than the broader lateral-transiliac literature. Device-specific percentages from any single paper should not be treated as your personal success rate. Ask which studies apply to the exact technique proposed for you.

Recovery After LinQ

You should receive written instructions for wound care, walking, weight bearing, assistive devices, medication, follow-up, and work restrictions. Early walking does not mean unrestricted loading is safe.

  • Use prescribed crutches or a walker and follow the exact weight-bearing plan.
  • Protect the incision and follow showering instructions.
  • Limit lifting, bending, twisting, and exercise as directed.
  • Start rehabilitation only when the operating clinician clears it.
  • Drive only when cleared, free of impairing medication, and able to move and brake safely.

Incision comfort can improve before fusion develops. Bone healing continues over months. Persistent or returning symptoms need reassessment—not an assumption of either success or failure. General timeline framing: SI joint fusion recovery on the hub page.

Risks and Alternatives

Potential risks include infection, bleeding or hematoma, nerve irritation or injury, graft malposition, migration or nonunion, fracture, persistent or worsening pain, anesthesia complications, and revision surgery. Small incisions do not erase internal risk. Allograft tissue pathways include donor screening and manufacturing controls aimed at communicable-disease risk; residual risk is not zero.

Alternatives may include ongoing rehab, therapeutic SI injection (if a steroid is used in the SI joint, that use is off-label), selected sacral lateral-branch RFA, SacriX or another fusion approach, and treatment of a different pain generator. Failed RFA does not automatically mean LinQ. Parent pathway: SI joint fusion hub.

Call 911 or go to the ER for sudden severe weakness, new bladder or bowel loss, saddle numbness, chest pain, or shortness of breath. Contact the team promptly for fever, drainage, spreading redness, wound opening, uncontrolled pain, or new weakness. Call 631-310-0000 for non-emergency questions.

Care at SpinePain Solutions

Dr. Amit Sharma, Chief, Division of Pain Medicine at Good Samaritan University Hospital, evaluates SI joint pain and fusion options at Bay Shore, Commack, and Farmingdale (office locations). He performs LinQ and SacriX himself when candidacy fits, uses bone graft in every fusion case, and explains tradeoffs without disparaging either system. Call or text 631-310-0000.

Frequently Asked Questions

What is LinQ SI joint fusion?

LinQ is a minimally invasive posterior SI joint procedure that places a structural cortical bone allograft within the sacroiliac joint to support stabilization and fusion. It does not use metal screws across the joint. Manufacturer: PainTEQ. It is one option within SI joint fusion, not a treatment for every cause of low-back or buttock pain.

When is SI joint pain an emergency instead?

Call 911 or go to the nearest emergency room for sudden severe leg weakness, new loss of bladder or bowel control, numbness in the saddle area, fever with severe back or pelvic pain, or rapidly worsening neurologic change. Elective LinQ visits are not for those emergencies. Call SpinePain Solutions at 631-310-0000 for non-emergency questions.

Is LinQ FDA-approved or FDA-cleared?

Peer-reviewed descriptions and manufacturer materials describe LinQ as a human cells, tissues, and cellular and tissue-based product (HCT/P) regulated under Section 361 of the Public Health Service Act and 21 CFR Part 1271—not as an FDA-cleared or FDA-approved 510(k) metal fixation device. That pathway focuses on communicable-disease controls. It is not the same as 510(k) device clearance. Ask which regulatory language applies to the exact implant planned for you.

Who might be a candidate for LinQ?

Candidates are typically people with persistent, function-limiting pain reasonably localized to the SI joint after conservative care, with competing lumbar and hip causes considered, and with a convincing response to image-guided diagnostic SI joint injection. Preference to avoid screws may enter the shared decision after tradeoffs are reviewed. No single test or injection percentage establishes candidacy alone.

How does LinQ differ from SacriX?

SacriX uses FDA-cleared titanium screws placed across the joint from a lateral-oblique corridor. LinQ places a structural allograft inside the joint from a posterior corridor without screws. They are different tools with different evidence shapes. Dr. Sharma often prefers SacriX for stability and offers LinQ for selected patients who prefer no screws after discussion. See the SI joint fusion hub and the SacriX page.

Where is the LinQ procedure done, and what is recovery like?

At SpinePain Solutions, SI joint fusion—including LinQ—is done in a hospital or surgery center setting. Many people go home the same day when medically appropriate. Early walking may begin with assistance, but weight-bearing limits, lifting restrictions, and return to work are individualized. Bone healing continues over months. Early comfort does not prove fusion is complete.

What are the main risks of LinQ?

Risks include infection, bleeding, nerve irritation or injury, graft malposition or failure to fuse (nonunion), fracture, persistent or worsening pain, anesthesia complications, and possible revision. A posterior allograft approach has different technical concerns than transiliac screw fixation. Small incisions do not eliminate internal surgical risk.

Ready to Take The Next Step?
Book an appointment with
Dr. Amit Sharma & our minimally invasive pain & spine team.
Same-day and urgent appointments are often available.

Medical References

  1. Calodney A, et al. Safety, Efficacy, and Durability of Outcomes: Results from SECURE… J Pain Res. 2024. PMID 38524688. NCT04423120.
  2. Calodney A, et al. Six Month Interim Outcomes from SECURE… Expert Rev Med Devices. 2022. PMID 35724479.
  3. McCormick ZL, et al. Consensus practice guidelines on sacroiliac joint complex pain… Reg Anesth Pain Med. 2025. PMID 41320235.
  4. Sayed D, et al. ASPN Best Practice Guideline for the Treatment of Sacroiliac Disorders. J Pain Res. 2024. PMID 38716038.
  5. Polly DW, et al. MIS SI fusion with triangular titanium implants vs nonsurgical management… Neurosurgery. 2015. PMID 26291338. (Lateral-implant context; not LinQ-specific.)
  6. Randers EM, et al. MIS SI fusion vs sham… EClinicalMedicine. 2024. PMID 38328752. (Not LinQ-specific; informs balanced fusion counseling.)
  7. U.S. FDA. Tissue & Tissue Product Q&A (HCT/P framework overview). FDA HCT/P Q&A.
  8. U.S. FDA. 510(k) K232605 SacriX® (comparator screw system; not LinQ). FDA record.
Medical disclaimer: This article is educational and is not a substitute for individualized medical evaluation. Decisions about injections, procedures, and surgery depend on examination, medical history, symptoms, imaging, and clinical judgment.

Dr. Amit Sharma, Chief, Division of Pain Medicine

Location Map:

Our Apps


APPatient App

Download on the App Store

Get it on Google Play
631-310-0000